A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE II STUDY OF VANDETANIB PLUS DOCETAXEL / PREDNISOLONE IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER